Controversies and challenges regarding the impact of radiation therapy on survival

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 38-46

  Chargari, C ^a,c   Soria, J C ^b   Deutsch, E ^a,b  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c University of Paris Descartes   (France)

Author keywords

Chemotherapy; Local control; Radiation therapy; Survival; Targeted agent

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; TEMOZOLOMIDE; TUMOR MARKER;

BREAST CANCER; CANCER CONTROL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED RADIOTHERAPY; DISTANT METASTASIS; DRUG CHOICE; DRUG FATALITY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; EVIDENCE BASED MEDICINE; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MASTECTOMY; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CARCINOMA; PATIENT SELECTION; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECTUM CARCINOMA; RECTUM SURGERY; RECURRENCE RISK; REVIEW; RISK REDUCTION; SOLID TUMOR; STUDY DESIGN; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

EID: 84871580598     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds217     Document Type: Review

References (69)

1. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensitymodulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001; 51: 880-914.
2. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006; 6: 449-458.
3. Suit HD, Westgate SJ. Impact of improved local control on survival. Int J Radiat Oncol Biol Phys 1986; 12: 453-458.
4. Punglia RS, Morrow M, Winer EP et al. Local therapy and survival in breast cancer. N Engl J Med 2007; 356: 2399-2405.
5. Fisher B, Jeong J-H, Anderson S et al. Twenty five- year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347: 567-575.
6. Veronesi U, Marubini E, Del Vecchio M et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995; 87: 19-27.
7. Fisher B, Anderson S, Bryant J et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-1241.
8. Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in high risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997; 337: 949-955.
9. Overgaard M, Jensen MB, Overgaard J et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641-1648.
10. Ragaz J, Olivotto IA, Spinelli JJ et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005; 97: 116-126.
11. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-2106.
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011; 378: 1707-1716.
13. Whelan TJ, Julian J, Wright J et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000; 18: 1220-1229.
14. Marcu LG. Altered fractionation in radiotherapy: from radiobiological rationale to therapeutic gain. Cancer Treat Rev 2010; 36: 606-614.
15. Bourhis J, Overgaard J, Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368: 843-854.
16. Saunders M, Dische S, Barrett A et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999; 52: 137-148.
17. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009; 74: 1405-1418.
18. Bartelink H, Horiot JC, Poortmans PM et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10- year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007; 25: 3259-3265.
19. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174.
20. Bradley JD, Paulus R, Komaki R et al. Randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy ± cetuximab for stage IIIA/IIIB non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617. In 53rd ASTRO Annual Meeting, Miami Beach, FL, USA. Abstract LBA2.
21. Molls M, Molls M, Anscher MS. The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies. Berlin: Springer 2009; 330-333.
22. Seeber LM, Horrée N, Vooijs MA et al. The role of hypoxia inducible factor- 1alpha in gynecological cancer. Crit Rev Oncol Hematol 2011; 78: 173-184.
23. Pignon JP, le Maître A, Maillard E et al.; MACH-NC Collaborative Group. Metaanalysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
24. O'Rourke N, Roqué I, Figuls M et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010: CD002140.
25. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. J Clin Oncol 2008; 26: 5802-5812.
26. Green JA, Kirwan JM, Tierney JF et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 358: 781-786.
27. Herskovic A, Martz K, al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598.
28. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006: CD002092.
29. Aupérin A, Le Péchoux C, Rolland E et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181-2190.
30. Noda SE, El-Jawahri A, Patel D et al. Molecular advances of brain tumors in radiation oncology. Semin Radiat Oncol 2009; 19: 171-178.
31. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
32. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
33. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
34. Glynne-Jones R, Mawdsley S, Harrison M. Cetuximab and chemoradiation for rectal cancer-is the water getting muddy? Acta Oncol 2010; 49: 278-286.
35. Ceelen W, Fierens K, Van Nieuwenhove Y et al Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer 2009; 124: 2966-2972.
36. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980-987.
37. Glynne-Jones R, Harrison M. Locally advanced rectal cancer: what is the evidence for induction chemoradiation? Oncologist 2007; 12: 1309-1318.
38. Patel UB, Taylor F, Blomqvist L et al Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011; 29: 3753-3760.
39. de Campos-Lobato LF, Stocchi L, da Luz Moreira A et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol 2011; 18: 1590-1598.
40. Moertel CG, Childs DS, Reitemeir RJ et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2: 865-867.
41. Moertel CG, Frytak S, Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (60 Gy) radiation alone, moderate dose radiation (40 Gy + 5-FU), and high dose radiation + 5-FU. The GITSG. Cancer 1981; 48: 1705-1710.
42. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19: 1592-1599.
43. Huguet F, André T, Hammel P et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25: 326-331.
44. Iacobuzio-Donahue CA, Fu B, Yachida S et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-1813.
45. Scalliet P, Goor C, Galdermans D et al. Gemzar® (gemcitabine) with thoracic radiotherapy - a phase II pilot study in chemonaive patients with advanced nonsmall cell lung cancer. Proc Am Soc Clin Oncol 1998; 17: 499a.
46. Loehrer PJ, Sr, Feng Y, Cardenes H et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29: 4105-4112.
47. Flatmark K, Ree AH. Radiosensitizing drugs: lessons to be learned from the oxaliplatin story. J Clin Oncol 2010; 28: 577-578.
48. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
49. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
50. Shiraishi K, Kohno T, Tanai C et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010; 28: 4945-4952.
51. Wang LE, Yin M, Dong Q et al. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol 2011; 29: 4121-4128.
52. Ebert MP, Tänzer M, Balluff B et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med 2012; 366: 44-53.
53. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
54. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
55. Erben P, Ströbel P, Horisberger K et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2011; 81: 1032-1038.
56. Grimminger PP, Danenberg P, Dellas K et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res 2011; 17: 3469-3477.
57. Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering firstline EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29: 2121-2127.
58. Ready N, Jänne PA, Bogart J et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGBstratified phase II trial. J Thorac Oncol 2010; 5: 1382-1390.
59. Tozer GM, Bicknell R. Therapeutic targeting of the tumor vasculature. Semin Radiat Oncol 2004; 14: 222-232.
60. Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-338.
61. Nutting CM, Morden JP, Harrington KJ et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-136.
62. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol 2007; 25: 953-964.
63. De Ruysscher D, Nestle U, Jeraj R et al. PET scans in radiotherapy planning of lung cancer. Lung Cancer 2012; 75: 141-145.
64. Takeda A, Yokosuka N, Ohashi T et al. The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized nonsmall- cell lung cancer after stereotactic body radiotherapy (SBRT). Radiother Oncol 2011; 101: 291-297.
65. Kawai N, Maeda Y, Kudomi N et al. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18Ffluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging 2011; 38: 441-450.
66. Dolgin E. Animal testing alternatives come alive in US. Nat Med 2010; 16: 1348.
67. Bianco C, Tortora G, Bianco R et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8: 3250-3258.
68. Troiani T, Schettino C, Martinelli E et al. The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Critical Rev Oncol Hematol 2008; 65: 200-211.
69. Yap TA, Sandhu SK, Workman P et al Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10: 514-523.